Cargando…

Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice

BACKGROUND: Synucleinopathies such as Parkinson’s disease or multiple system atrophy are characterized by Lewy bodies in distinct brain areas. These aggregates are mainly formed by α-synuclein inclusions, a protein crucial for synaptic functions in the healthy brain. Transgenic animal models of synu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rabl, R., Breitschaedel, C., Flunkert, S., Duller, S., Amschl, D., Neddens, J., Niederkofler, V., Rockenstein, E., Masliah, E., Roemer, H., Hutter-Paier, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282838/
https://www.ncbi.nlm.nih.gov/pubmed/28143405
http://dx.doi.org/10.1186/s12868-017-0341-8
_version_ 1782503402028138496
author Rabl, R.
Breitschaedel, C.
Flunkert, S.
Duller, S.
Amschl, D.
Neddens, J.
Niederkofler, V.
Rockenstein, E.
Masliah, E.
Roemer, H.
Hutter-Paier, B.
author_facet Rabl, R.
Breitschaedel, C.
Flunkert, S.
Duller, S.
Amschl, D.
Neddens, J.
Niederkofler, V.
Rockenstein, E.
Masliah, E.
Roemer, H.
Hutter-Paier, B.
author_sort Rabl, R.
collection PubMed
description BACKGROUND: Synucleinopathies such as Parkinson’s disease or multiple system atrophy are characterized by Lewy bodies in distinct brain areas. These aggregates are mainly formed by α-synuclein inclusions, a protein crucial for synaptic functions in the healthy brain. Transgenic animal models of synucleinopathies are frequently based on over-expression of human wild type or mutated α-synuclein under the regulatory control of different promoters. A promising model is the Line 61 α-synuclein transgenic mouse that expresses the transgene under control of the Thy-1 promoter. RESULTS: Here, we show an extended characterization of this mouse model over age. To this end, we analyzed animals for the progression of human and mouse protein expression levels in different brain areas as well as motor and memory deficits. Our results show, that Line 61 mice exhibited an age dependent increase of α-synuclein protein levels in the hippocampus but not the striatum. While murine α-synuclein was also increased with age, it was lower expressed in Line 61 mice than in non-transgenic littermates. At the age of 9 months animals exhibited increased neuroinflammation. Furthermore, we found that Line 61 mice showed severe motor deficits as early as 1 month of age as assessed by the wire hanging and nest building tests. At later ages, initial motor deficits were validated with the RotaRod, pasta gnawing and beam walk tests. At 8 months of age animals exhibited emotional memory deficits as validated with the contextual fear conditioning test. CONCLUSION: In summary, our results strengthen and further expand our knowledge about the Line 61 mouse model, emphasizing this mouse model as a valuable in vivo tool to test new compounds directed against synucleinopathies.
format Online
Article
Text
id pubmed-5282838
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52828382017-02-03 Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice Rabl, R. Breitschaedel, C. Flunkert, S. Duller, S. Amschl, D. Neddens, J. Niederkofler, V. Rockenstein, E. Masliah, E. Roemer, H. Hutter-Paier, B. BMC Neurosci Research Article BACKGROUND: Synucleinopathies such as Parkinson’s disease or multiple system atrophy are characterized by Lewy bodies in distinct brain areas. These aggregates are mainly formed by α-synuclein inclusions, a protein crucial for synaptic functions in the healthy brain. Transgenic animal models of synucleinopathies are frequently based on over-expression of human wild type or mutated α-synuclein under the regulatory control of different promoters. A promising model is the Line 61 α-synuclein transgenic mouse that expresses the transgene under control of the Thy-1 promoter. RESULTS: Here, we show an extended characterization of this mouse model over age. To this end, we analyzed animals for the progression of human and mouse protein expression levels in different brain areas as well as motor and memory deficits. Our results show, that Line 61 mice exhibited an age dependent increase of α-synuclein protein levels in the hippocampus but not the striatum. While murine α-synuclein was also increased with age, it was lower expressed in Line 61 mice than in non-transgenic littermates. At the age of 9 months animals exhibited increased neuroinflammation. Furthermore, we found that Line 61 mice showed severe motor deficits as early as 1 month of age as assessed by the wire hanging and nest building tests. At later ages, initial motor deficits were validated with the RotaRod, pasta gnawing and beam walk tests. At 8 months of age animals exhibited emotional memory deficits as validated with the contextual fear conditioning test. CONCLUSION: In summary, our results strengthen and further expand our knowledge about the Line 61 mouse model, emphasizing this mouse model as a valuable in vivo tool to test new compounds directed against synucleinopathies. BioMed Central 2017-01-31 /pmc/articles/PMC5282838/ /pubmed/28143405 http://dx.doi.org/10.1186/s12868-017-0341-8 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Rabl, R.
Breitschaedel, C.
Flunkert, S.
Duller, S.
Amschl, D.
Neddens, J.
Niederkofler, V.
Rockenstein, E.
Masliah, E.
Roemer, H.
Hutter-Paier, B.
Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice
title Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice
title_full Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice
title_fullStr Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice
title_full_unstemmed Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice
title_short Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice
title_sort early start of progressive motor deficits in line 61 α-synuclein transgenic mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282838/
https://www.ncbi.nlm.nih.gov/pubmed/28143405
http://dx.doi.org/10.1186/s12868-017-0341-8
work_keys_str_mv AT rablr earlystartofprogressivemotordeficitsinline61asynucleintransgenicmice
AT breitschaedelc earlystartofprogressivemotordeficitsinline61asynucleintransgenicmice
AT flunkerts earlystartofprogressivemotordeficitsinline61asynucleintransgenicmice
AT dullers earlystartofprogressivemotordeficitsinline61asynucleintransgenicmice
AT amschld earlystartofprogressivemotordeficitsinline61asynucleintransgenicmice
AT neddensj earlystartofprogressivemotordeficitsinline61asynucleintransgenicmice
AT niederkoflerv earlystartofprogressivemotordeficitsinline61asynucleintransgenicmice
AT rockensteine earlystartofprogressivemotordeficitsinline61asynucleintransgenicmice
AT masliahe earlystartofprogressivemotordeficitsinline61asynucleintransgenicmice
AT roemerh earlystartofprogressivemotordeficitsinline61asynucleintransgenicmice
AT hutterpaierb earlystartofprogressivemotordeficitsinline61asynucleintransgenicmice